on the money, page-2

Someone else asked this recently so I sat down and thought about it....

Looking at the cash position from Jun 30 2015, we should have 2 years worth of cash at least. So let's be pessimistic and say they go for a raise towards the end of next year (last raise was in Nov 2013)

By then we should have:

Ph II FXS
Ph II TBI
Ph II Rett paediatric
maybe Ph II concussion.

I think, given previous positive Ph II Rett results, the Rett trial is most likely to succeed. So you could imagine raising 20-30m to run the Ph III trial. So my worst case scenario is that the next Rett trial is the only one of these four that succeeds.

The question is: if we are good for Rett but not for anything else, how should the company be valued? We've been hovering at 8-10c since we missed BT so that's probably the worst case. The risk is that failed trial results for the other conditions somehow poison in investor's minds the success of the Rett trial.

If one of the other Ph II trials is successful, then in theory the NEU price should be much higher, so at a market cap of, say, 300-400m the dilution is not so bad.

But NEU do not have to rush for cash for a while so I don't think this is a question we have to ask until at least the end of the year.